Glucose-6-phosphate translocase deficiency
Glucose-6-phosphate translocase deficiency is a rare genetic disorder that affects the body's ability to regulate blood sugar levels. This condition is part of a group of diseases known as Glycogen Storage Diseases (GSDs), specifically classified as type 1b. It is caused by mutations in the SLC37A4 gene, which encodes the glucose-6-phosphate translocase enzyme. This enzyme is crucial for the proper functioning of the gluconeogenesis and glycogenolysis pathways, which are responsible for maintaining stable blood glucose levels.
Symptoms and Diagnosis[edit | edit source]
Individuals with glucose-6-phosphate translocase deficiency typically present symptoms in infancy or early childhood. The hallmark symptoms include hypoglycemia (low blood sugar levels), growth retardation, and a distended abdomen due to an enlarged liver (hepatomegaly). Other symptoms may include neutropenia (a reduction in the number of white blood cells), which increases susceptibility to infections, and a condition known as inflammatory bowel disease (IBD).
Diagnosis of glucose-6-phosphate translocase deficiency is based on clinical presentation, biochemical tests showing abnormal blood sugar and lactate levels, and genetic testing confirming mutations in the SLC37A4 gene.
Treatment[edit | edit source]
Management of glucose-6-phosphate translocase deficiency involves maintaining normal blood glucose levels through dietary interventions. This includes frequent, carbohydrate-rich meals and the administration of uncooked cornstarch, which provides a slow-release form of glucose. In cases of neutropenia, antibiotics may be prescribed to prevent or treat infections. Growth hormone therapy may be considered for patients experiencing significant growth retardation.
Genetics[edit | edit source]
The SLC37A4 gene mutations responsible for glucose-6-phosphate translocase deficiency are inherited in an autosomal recessive pattern. This means that an individual must inherit two copies of the mutated gene, one from each parent, to be affected by the disorder. Carriers, who have only one copy of the mutation, typically do not show symptoms of the disease.
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
